This Article Full Text Full Text (PDF) Submit a related Letter to the Editor Alert me when this article is cited Alert me when eLetters are posted Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Copyright Permission Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Jehle, S. Articles by Freda, P. U. Search for Related Content PubMed PubMed Citation Articles by Jehle, S. Articles by Freda, P. U. Related Collections Neuroendocrinology and Pituitary Diabetes and Insulin

Alternate-Day Administration of Pegvisomant Maintains Normal Serum Insulin-Like Growth Factor-I Levels in Patients with Acromegaly

Department of Medicine, Columbia College of Physicians and Surgeons, New York, New York 10032

Address all correspondence and requests for reprints to: Pamela U. Freda, M.D., Department of Medicine, Columbia College of Physicians and Surgeons, 630 West 168th Street, New York, New York 10032. E-mail: puf1{at}columbia.edu.

IGF-I levels normalize in the majority of patients with acromegaly treated with the GH receptor antagonist pegvisomant. To date, the efficacy of pegvisomant has been demonstrated with daily administration of doses ranging from 10 to 40 mg. However, given the known long half-life of the drug in circulation, we hypothesized that dosing less frequently than daily would still maintain the drug’s efficacy. We studied 10 patients with active acromegaly treated with pegvisomant. This therapy was begun at 10 mg daily but then titrated up in dose or down to alternate-day dosing to try to maintain serum IGF-I levels in the upper half of the patients’ age-adjusted normal range. We found that in five of 10 patients, serum IGF-I levels remained normal on less frequent than daily pegvisomant. Signs and symptoms of the disease and a disease-related morbidity, insulin resistance, remained improved in these patients. We demonstrate for the first time the continued efficacy of alternate-day administration of pegvisomant.

This article has been cited by other articles:

				C E Higham, J D J Thomas, M Bidlingmaier, W M Drake, and P J Trainer Successful use of weekly pegvisomant administration in patients with acromegaly Eur. J. Endocrinol., July 1, 2009; 161(1): 21 - 25. [Abstract] [Full Text] [PDF]

				M Rix, P Laurberg, A S Hoejberg, and B Brock-Jacobsen Pegvisomant therapy in pituitary gigantism: successful treatment in a 12-year-old girl Eur. J. Endocrinol., August 1, 2005; 153(2): 195 - 201. [Abstract] [Full Text] [PDF]